THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Whatever happened to the next big thing?

$8b Millennium deal serves up reality check on lofty genomics expectations

By Jeffrey Krasner
Globe Staff / April 11, 2008

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

The genomics revolution was not a flop. It just needs more time. Millennium Pharmaceuticals Inc. , the Cambridge biotech firm that came to symbolize the genomics breakthroughs of the past 10 years, was never able to both develop and market a single drug using its genomic expertise. Yesterday, Japanese drug maker Takeda Pharmaceutical Co. said it would buy the company ... (Full article: 753 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass